Connect with us

Business

Why Vertex Pharmaceuticals Stock Is Slumping Today – Motley Fool

Investors are concerned about Vertex’s pipeline after a rare miss in the clinic.

Published

on

post featured image
ADVERTISEMENT

What happened
Shares of rare-disease specialist Vertex Pharmaceuticals(NASDAQ:VRTX) fell by as much as 15.7% in pre-market trading Thursday morning. The biotech’s stock is under pressure today due to a worrying safety signal observed in a midstage trial for the small-molecule drug VX-814 as a potential treatment for alpha-1 antitrypsin deficiency (AATD). 
Specifically, the drug’s development is reportedly being discontinued after several patients in the study exhibited elevated liver enzymes….

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

post featured image
Rubio’s Files for Bankruptcy; Restaurants Remain Open – NBC San Diego
post featured image
Milwaukee reverses order, issues new restrictions to limit virus spread – WISN Milwaukee
IRS Releases 2021 Tax Rates, Standard Deduction Amounts And More – Forbes